Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: An open-label phase 2 trial

The Lancet Oncology

Volumn 16, Issue 2, 2015, Pages 177-186

  Thomas, Anish ^a   Rajan, Arun ^a   Berman, Arlene ^a   Tomita, Yusuke ^a   Brzezniak, Christina ^c   Lee, Min Jung ^a   Lee, Sunmin ^a   Ling, Alexander ^b   Spittler, Aaron J ^d   Carter, Corey A ^c   Guha, Udayan ^a   Wang, Yisong ^e   Szabo, Eva ^a   Meltzer, Paul ^a   Steinberg, Seth M ^a   Trepel, Jane B ^a   Loehrer, Patrick J ^d   Giaccone, Giuseppe ^e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^e GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER PAIN; CANCER SURVIVAL; CHOLECYSTITIS; CLINICAL ARTICLE; COUGHING; DIARRHEA; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRY SKIN; DYSGEUSIA; DYSPEPSIA; DYSPNEA; FACE EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HAND FOOT SYNDROME; HEADACHE; HEART ARREST; HEART LEFT VENTRICLE EJECTION FRACTION; HISTOLOGY; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; HYPOXIA; LUNG INFECTION; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; MALE; MOUTH PAIN; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; ORAL MUCOSITIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREATITIS; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; THORAX PAIN; THYMOMA; THYMUS CANCER; TREATMENT DURATION; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT; VOMITING; XEROSTOMIA; CANCER STAGING; CLINICAL TRIAL; DRUG EFFECTS; DRUG RESISTANCE; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; NEUROENDOCRINE TUMORS; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; THYMUS NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PROGNOSIS; PYRROLES; SURVIVAL RATE; THYMOMA; THYMUS NEOPLASMS;

EID: 84921841165     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)71181-7     Document Type: Article

References (32)

1. Engels EA, Pfeiffer RM Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer 2003, 105:546-551.
2. Kuo TT Tumors of the thymus. WHO classification of tumors: pathology and genetics of tumors of the lung, pleura, thymus and heart 2004, 146-248. IARC Press, Lyon. W.D. Travis, E. Brambilla, H.K. Muller-Hermelink, C.C. Harris (Eds.).
3. Margaritora S, Cesario A, Cusumano G, et al. Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. Ann Thorac Surg 2010, 89:245-252.
4. Loehrer PJ, Kim K, Aisner SC, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. J Clin Oncol 1994, 12:1164-1168. The Eastern Cooperative Oncology Group, Southwest Oncology GroupSouthwest Oncology Group, Southeastern Cancer Study GroupSoutheastern Cancer Study Group.
5. Okuma Y, Saito M, Hosomi Y, Sakuyama T, Okamura T Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy. J Cancer Res Clin Oncol 2014, published online Aug 22. http://dx.doi.org/10.1007/s00432-014-1800-6.
6. Rajan A, Carter CA, Berman A, et al. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncol 2014, 15:191-200.
7. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003, 101:3597-3605.
8. Cimpean AM, Raica M, Encica S, Cornea R, Bocan V Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus. Ann Anat 2008, 190:238-245.
9. Tomita M, Matsuzaki Y, Edagawa M, et al. Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors. J Thorac Cardiovasc Surg 2002, 124:493-498.
10. Sasaki H, Yukiue H, Kobayashi Y, et al. Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms. Surg Today 2001, 31:1038-1040.
11. Pan CC, Chen PC, Chiang H KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 2004, 202:375-381.
12. Petrini I, Zucali PA, Lee HS, et al. Expression and mutational status of c-kit in thymic epithelial tumors. J Thorac Oncol 2010, 5:1447-1453.
13. Cimpean AM, Ceausu R, Encica S, Gaje PN, Ribatti D, Raica M Platelet-derived growth factor and platelet-derived growth factor receptor-alpha expression in the normal human thymus and thymoma. Int J Exp Pathol 2011, 92:340-344.
14. Bisagni G, Rossi G, Cavazza A, Sartori G, Gardini G, Boni C Long lasting response to the multikinase inhibitor Bay 43-9006 (sorafenib) in a heavily pretreated metastatic thymic carcinoma. J Thorac Oncol 2009, 4:773-775.
15. Strobel P, Bargou R, Wolff A, et al. Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer 2010, 103:196-200.
16. Hoffacker V, Schultz A, Tiesinga JJ, et al. Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease. Blood 2000, 96:3872-3879.
17. Finke JH, Rini B, Ireland J, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008, 14:6674-6682.
18. Ozao-Choy J, Ma G, Kao J, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009, 69:2514-2522.
19. Petrini I, Meltzer PS, Kim IK, et al. A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nat Genet 2014, 46:844-849.
20. Wang Y, Thomas A, Lau C, et al. Mutations in epigenetic regulatory genes are common in thymic carcinomas. Sci Rep (in press).
21. Atkinson EN, Brown BW Confidence limits for probability of response in multistage phase II clinical trials. Biometrics 1985, 41:741-744.
22. Okuma Y, Hosomi Y, Takagi Y, et al. Clinical outcomes with chemotherapy for advanced thymic carcinoma. Lung Cancer 2013, 80:75-80.
23. Zettl A, Strobel P, Wagner K, et al. Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol 2000, 157:257-266.
24. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007, 370:2011-2019.
25. Thomas A, Shanbhag S, Haglund K, et al. Characterization and management of cardiac involvement of thymic epithelial tumors. J Thorac Ooncol 2013, 8:246-249.
26. Hernandez-Yanez M, Heymach JV, Zurita AJ Circulating biomarkers in advanced renal cell carcinoma: clinical applications. Curr Oncol Rep 2012, 14:221-229.
27. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 2008, 319:195-198.
28. Haber DA, Velculescu VE Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov 2014, 4:650-661.
29. Legat A, Speiser DE, Pircher H, Zehn D, Fuertes Marraco SA Inhibitory receptor expression depends more dominantly on differentiation and activation than "exhaustion" of human CD8 T cells. Front Immunol 2013, 4:455.
30. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
31. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
32. Girard N Thymic tumors: relevant molecular data in the clinic. J Thorac Oncol 2010, 5(10 suppl 4):S291-S295.